This experimental technique is being studied to see whether it could treat certain health problems.
Gaps in the current practice of reporting deaths due to main disease progression in clinical trials.
The article delineates that ameliorations in trial duration were most likely a result of increasing protocol complexity/trial design, numerous endpoints, increases in the number of subjects required, and longer treatment periods.
Will emerging drug cost assessment initiatives provide useful, valid information on total drug value?
This month marks a landmark in the quest for personalized medicine and the growing role of big data in health sciences – from clinical development through tracking patient outcomes long after a therapy has reached the market.
Randomized Clinical Trials (RCTs) have constituted the foundation for new drug approvals for over fifty years.
Few topics occasion the lamentations of clinical trial professionals more than the topic of patient inclusion/exclusion criteria in clinical protocols.
Accuracy in data capture methods has always been and will continue to be a foremost necessity in pharmaceutical clinical trials.
By Pem Guerry
Across the pharmaceutical industry, advances in digital technology play a key role in driving the efficiency of the drug development process, particularly for clinical trials.
By Jud Gardner
Clinical trials are time sensitive, costly endeavors with high-risk and high-expectations at every juncture.
This latest, updated eBook on Risk-Based Monitoring from Applied Clinical Trials includes the latest information on the topic being discussed around clinical trials. Includes pitfalls to avoid when implementing an RBM strategy, and an update on Cancer Research UK's implementation.
Every trial starts with a budget, and a clinical trial study start-up process that can be fraught with delays. From contract negotiations, to managing a trial for a sponsor, to streamlining study start-up process, this eBook seeks to instruct others on best practices.
With a growing need for post-marketing safety databases, and increased need to collect qualitative information from patients in the pre- and post-market of a drug the evidence gathering from clinical trials onward is expanding.